The Acute coronary syndrome pipeline therapeutics pipeline is expected
to increase on account of increasing population, which are at risk of severe
cardiovascular disease. High blood pressure, uncontrollable blood sugar level,
hypercholesterolemia, smoking are the main causes of developing acute coronary
syndrome.
Access Report Overview: https://www.psmarketresearch.com/market-analysis/acute-coronary-syndrome-therapeutics-pipeline-analysis
Sometimes, stroke, emotional trauma also make a platform for emerging
abnormalities in cardiovascular system. Amendments in lifestyle, routine and
habit makes a big difference for increasing continuum of cardiovascular
disease. Cumulative growth of pipeline is expected to grow as long as the arena
of morbidities due to cardiovascular disease is occurring. In 2009, around 18%
of men and 23% of women in United States were at risk of myocardial infarction,
accordingly American Heart Association. Increasing the hospital therapy cost
also a floating factor for expanding pipeline growth of acute coronary syndrome
because it is a make-up of many diseases like myocardial ischemia, unstable
angina, myocardial infarction etc.
Download Free Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/acute-coronary-syndrome-therapeutics-pipeline-analysis/report-sample
In June 2015, Sun Pharmaceutical Industries Ltd. and AstraZeneca Pharma
India Limited (AZPIL) have entered into a distribution services agreement in
India for AstraZeneca’s brand “Axcer”, a new brand of ticagrelor, a drug used
for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand
under the trademark “Brilinta”, for ticagrelor molecule, which was launched and
marketed by AZPIL in India since 2012.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-coronary-syndrome-therapeutics-pipeline-analysis
Some of the companies having a
pipeline of acute coronary syndrome therapeutics include, Roche Molecular
Systems, Inc, MedImmune, LLC, AstraZeneca Plc, SIS Medical AG, Asklepion
Pharmaceuticals, LLC, Genentech, Inc., GlaxoSmithKline plc.
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
No comments:
Post a Comment